28.25% percent quarterly performance for Protagonist Therapeutics Inc (PTGX) is not indicative of the underlying story

On Tuesday, Protagonist Therapeutics Inc (NASDAQ: PTGX) was -1.84% drop from the session before settling in for the closing price of $46.76. A 52-week range for PTGX has been $14.78 – $48.89.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Healthcare Sector giant saw their annual sales surged by 2462.45% over the last five years. When this article was written, the company’s average yearly earnings per share was at 272.30%. With a float of $55.65 million, this company’s outstanding shares have now reached $57.71 million.

The firm has a total of 112 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.94%, operating margin of 47.71%, and the pretax margin is 54.09%.

Protagonist Therapeutics Inc (PTGX) Insider Activity

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Protagonist Therapeutics Inc stocks. The insider ownership of Protagonist Therapeutics Inc is 5.52%, while institutional ownership is 101.27%. The most recent insider transaction that took place on Sep 11 ’24, was worth 631,872. In this transaction Chief Financial Officer of this company sold 14,203 shares at a rate of $44.49, taking the stock ownership to the 34,960 shares. Before that another transaction happened on Sep 10 ’24, when Company’s Director sold 8,000 for $45.00, making the entire transaction worth $360,000. This insider now owns 12,000 shares in total.

Protagonist Therapeutics Inc (PTGX) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around 272.30% per share during the next fiscal year.

Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators

You can see what Protagonist Therapeutics Inc (PTGX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 13.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.47. Likewise, its price to free cash flow for the trailing twelve months is 11.71.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.63, a number that is poised to hit -0.58 in the next quarter and is forecasted to reach -0.58 in one year’s time.

Technical Analysis of Protagonist Therapeutics Inc (PTGX)

Analysing the last 5-days average volume posted by the [Protagonist Therapeutics Inc, PTGX], we can find that recorded value of 0.47 million was lower than the volume posted last year of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 40.10%. Additionally, its Average True Range was 1.60.

During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 83.59%, which indicates a significant increase from 40.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.23% in the past 14 days, which was lower than the 39.20% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $45.25, while its 200-day Moving Average is $34.74. Now, the first resistance to watch is $47.52. This is followed by the second major resistance level at $49.14. The third major resistance level sits at $50.97. If the price goes on to break the first support level at $44.07, it is likely to go to the next support level at $42.24. Should the price break the second support level, the third support level stands at $40.62.

Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats

There are 58,905K outstanding shares of the company, which has a market capitalization of 2.70 billion. As of now, sales total 60,000 K while income totals -78,960 K. Its latest quarter income was 4,170 K while its last quarter net income were -30,620 K.